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Abstract
Background
Sterile protection in >90% of volunteers against homologous Plasmodium falciparum infec-
tion has been achieved only using the controlled human malaria infection (CHMI) model.
This efficient model involves whole parasite immunizations under chloroquine prophylaxis
(CPS-immunization), requiring only 30–45 mosquitoes bites infected with P. falciparum-
sporozoites. Given the large diversity of P. falciparum parasites, it is essential to assess pro-
tection against heterologous parasite strains.
Methods
In an open-label follow-up study, 16 volunteers previously CPS-immunized and challenged
with P. falciparum NF54 (West-Africa) in a dose de-escalation and challenge trial were re-
challenged with clone NF135.C10 (Cambodia) at 14 months after the last immunization
(NCT01660854).
Results
Two out of thirteen NF54 protected volunteers previously fully protected against NF54 were
also fully protected against NF135.C10, while 11/13 showed a delayed patency (median
prepatent period of 10.5 days (range 9.0–15.5) versus 8.5 days in 5 malaria-naïve controls
(p = 0.0005). Analysis of patency by qPCR indicated a 91 to >99% estimated reduction of
liver parasite load in 7/11 partially protected subjects. Three volunteers previously not pro-
tected against NF54, were also not protected against NF135.C10.
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Conclusion
This study shows that CPS-immunization can induce heterologous protection for a period of
more than one year, which is a further impetus for clinical development of whole parasite
vaccines.
Trial Registration
Clinicaltrials.gov NCT01660854
Introduction
Malaria remains a tremendous public health problem affecting approximately 40% of the
world’s population. The global incidence of malaria is estimated to be around 198 million clini-
cal cases resulting in 584.000 deaths [1] most of which are caused by P. falciparum. Since cur-
rent interventions fail to reduce malaria incidence sufficiently, a vaccine is urgently needed to
combat this disease.
Sterile protection against P. falciparummalaria can efficiently and reproducibly be achieved
in the Controlled Human Malaria Infection (CHMI) setting by repeated inoculation of live
sporozoites by bites of laboratory-reared Anophelesmosquitoes to healthy malaria-naïve vol-
unteers under chemoprophylaxis: ChemoProphylaxis and Sporozoites (CPS-) immunization
[2,3]. CPS-induced protection is dose-dependent [3] and was shown in a subset of volunteers
to last for more than two years [4]. Furthermore, bites from only 30–45 P. falciparum-infected
mosquitoes are sufficient to induce sterile protection in>90% of subjects, while immunization
with radiation-attenuated sporozoites (RAS) requires a minimum of 1,000 P. falciparum-in-
fected mosquitoes, or intravenous injection of 675,000 cryopreserved sporozoites [5,6]. So far
CPS-immunizations and challenges have been performed with the homologous NF54 strain
only, while in malaria-endemic areas there is a large genetic and antigenic diversity of P. falcip-
arum strains. This diversity is considered an important reason why naturally acquired immuni-
ty is obtained slowly, only after several years of repeated exposure [7]. Previously, heterologous
protection has been reported in 4/6 RAS-immunized volunteers [5].
Next to the widely used P. falciparum strain NF54 and its clone 3D7, NF135.C10 originating
from Cambodia has become available for CHMI studies [7]. In this study, volunteers who had
previously participated in a NF54 dose de-escalation CPS-immunization and challenge trial
were re-challenged with NF135.C10 after more than one year.
Materials and Methods
The protocol for this trial and supporting TREND checklist are available as supporting infor-
mation; see S1 Checklist and S1 Protocol.
Study design
A single centre open label clinical trial was conducted at the Leiden University Medical Center
(LUMC) from July 2012 until February 2013. The study was approved by the Central Commit-
tee for Research Involving Human Subjects of The Netherlands (NL39414.000.12) and com-
plied with the Declaration of Helsinki and Good Clinical Practice including monitoring of
data. ClinicalTrials.gov Identifier: NCT01660854.
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Study participants
Eighteen volunteers from a NF54 CPS dose-de-escalating study (ClinicalTrials.gov Identifier:
NCT01218893;[8]) and 8 newly recruited malaria-naïve subjects aged 18–35 years were all
screened in July 2012 for eligibility based on medical and family history, physical examination
and standard haematological and biochemical measurements (Fig 1). Seventeen NF54 CPS-
immunized volunteers and five controls were included. One volunteer had to be excluded be-
cause of a positive urine toxicology test for cannabis and was treated with atovaquone/progua-
nil two days after challenge. Two of the remaining included volunteers had previously received
Fig 1. Study flow diagram. The previous NF54 CPS-immunization study is shown in grey. P = NF54
protected, NP = NF54 unprotected.⊗ = Volunteer presumptively treated on day 10.5 after NF54 challenge
and considered NF54 protected
doi:10.1371/journal.pone.0124243.g001
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the highest dose of NF54 CPS (3x15 bites), 8 a medium dose (3x10 bites) and 6 the lowest dose
(3x5 bites). Thirteen were NF54 protected, of which one volunteer was presumptively treated
because of a non-malaria related SAE on day 10,5 after NF54 challenge but considered NF54
protected [8]. The sample size calculation for this study is described in detail in S1 Methods.
None of the female volunteers were pregnant or lactating. Serology for HIV, hepatitis B and
hepatitis C was negative in all volunteers. Plasma samples tested by Enzyme-Linked Immuno-
Sorbent Assay (ELISA) against crude NF54 asexual blood stages were negative in all control
volunteers. None of the volunteers had travelled to a malaria-endemic area within 6 months
prior to the start of the study. All volunteers provided written informed consent before
screening.
Study procedures
All volunteers were challenged simultaneously by exposure to five bites of Anopheles stephensi
mosquitoes infected with the NF135.C10 P. falciparum clone in August 2012 [9]. This heterolo-
gous challenge was performed 14 months after the last NF54 CPS-immunization and 9.5
months after NF54 challenge. Volunteers were followed-up on an outpatient basis once daily
on days 5–6 after challenge, twice daily between days 7–15 and once daily between days 16–21.
During each visit, blood was drawn for parasite detection by thick smear. Volunteers were
treated with 1000 mg atovaquone and 400 mg proguanil once daily for three days according to
Dutch national malaria guidelines as soon as parasites were detected by thick smear, or on day
21 after challenge if they had remained thick smear negative. The last visit for volunteers was
conducted in February 2013.
Safety parameters were determined daily: platelet counts were determined in EDTA blood
with the Sysmex XE-2100 (Sysmex Europe GmbH. Norderstedt. Germany). D-dimer concen-
trations were assessed in citrate plasma by STA-R Evolution (Roche Diagnostics, Almere, The
Netherlands; upper limit of detection 5000 ng/ml), Highly sensitive (Hs) Troponine T and Lac-
tate Hydrogenase (LDH) were determined in serum by Modular E170 (Roche Diagnostics, Al-
mere, The Netherlands).
Endpoints
The primary endpoint was time to parasitemia after challenge infection as assessed by thick
smear. Blood was screened by microscopy for parasites as described before, and the thick
smear was considered positive if two unambiguous parasites were detected in 0.5μL of blood,
confirmed by a second independent reader. Volunteers were considered protected when thick
smear remained negative up until 21 days after challenge.
Secondary endpoints were the kinetics of parasitemia and frequency of signs and symptoms.
Parasitemia was retrospectively quantified by qPCR on samples collected up to twice daily
from day 5 until day 21 after challenge as described previously [10] with some modifications.
Briefly, 5μL Zap-oglobin II Lytic Reagent (Beckman Coulter) was added to 0.5ml of EDTA
blood, after which the samples were mixed and stored at -80°C. After thawing, samples were
spiked with the extraction control Phocine Herpes Virus (PhHV) and DNA was extracted with
a MagnaPure LC isolation station. Isolated DNA was resuspended in 50μl H2O and 5μl was
used as template. For the detection of P. falciparum, the primers as described earlier [10] and
the TaqMan MGB FAM-labelled probe 5’-AACAATTGGAGGGCAAG-3’ were used. For
quantification of PhHV the primers 5’-GGGCGAATCACAGATTGAATC-3’, 5’-GCGGTT
CCAAACGTACCAA-3’ and the probe Cy5-5’-TTTTTATGTGTCCGCCACCATCTGGAT
C-3’ were used.
Heterologous Protection against Malaria
PLOS ONE | DOI:10.1371/journal.pone.0124243 May 1, 2015 4 / 10
Adverse events (AE) reported by volunteers or observed by the investigator were recorded
according to the following scale:mild (grade 1; easily tolerated),moderate (grade 2; interferes
with normal activity) or severe (grade 3; prevents normal activity). Fever was recorded as grade
1 (37.5–38.0°C), grade 2 (38.0–39.0°C) or grade 3 (>39.0°C).
Statistical analysis
All possibly and probably (both solicited and unsolicited) related AE were tabulated, grouped
and analysed by calculating the average number of mild, moderate or severe AE per volunteer
in each group. Statistical analyses were performed using GraphPad Prism 6.02. Differences in
prepatent period and parasitemia at time of treatment between two groups (NF54 protected
and controls) were tested by MannWhitney test, and between the three dose groups by Krus-
kal-Wallis test with Dunn’s multiple comparison post-hoc test. A p value of<0.05 was consid-
ered statistically significant.
Results
Heterologous protection induced by CPS-immunization
Sterile heterologous protection against NF135.C10 was complete in 15% (2/13) of NF54 pro-
tected volunteers (Fig 2A). Patency was significantly delayed in the other 11 volunteers, indica-
tive of partial protection (median prepatent period determined by thick smear was 10.5 days
[range 9.0–15.5] versus 8.5 days [range 8.5–8.5] in controls; p = 0.0005 (Table 1, Fig 2B).
Seven out of 11 partially protected subjects showed a delay in patency by qPCR of at least 48
hours, and thus more than one P. falciparummultiplication cycle.
The 3 volunteers previously not protected against NF54 were neither protected against
NF135.C10 (Table 1, Fig 1). The prepatent period by thick smear did not differ significantly
between NF54 CPS-immunization dose groups (Fig 2C and 2D). Parasitemia at time of treat-
ment was higher in controls compared to CPS immunized (p = 0.047; Fig 3).
Adverse events
We next analysed adverse events in relation to the day of treatment to determine any early
blood stage immune recognition to the parasite reflected in AE. Adverse events experienced by
volunteers represent clinical manifestations of a malaria infection and can be possibly and
probably related (both solicited and unsolicited) to the infection.
All volunteers reported possibly or probably related AE after challenge. Partially protected
volunteers and controls showed a peak of AE on the first day after start of treatment (Fig 4).
Fourteen volunteers experienced related grade 3 AE, which were more frequently reported in
partially protected than in control volunteers (8/10 versus 2/5 respectively). There were no seri-
ous AE. In partially protected volunteers, delayed patency concurred with earlier onset of AE
in relation to detection of parasites by thick smear. While control volunteers did not experience
any AE up until one day before detection of parasites by thick smear, partially protected volun-
teers experienced AE as early as three days before initiation of treatment.
All controls and one partially protected volunteer showed persisting fever (maximum
39.0°C) and/or mild to moderate complaints in the evening of day 3 after start of treatment.
Resolution of the AE took longer (up to 7 days) in controls compared to partially protected vol-
unteers, and to historical controls [11]. Additional thick smears performed in these volunteers
on day 4, 5 and 6 after start of treatment were negative. All volunteers recovered fully without
requiring additional antimalarial treatment.
Heterologous Protection against Malaria
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Safety parameters
Hs troponin T concentrations remained within normal range (<0.03 μg/L) in all volunteers.
LDH was elevated in ten volunteers after initiation of treatment (median maximum value 242
U/L, range 182–718 U/L) and returned within normal range (0–248 U/L) during follow-up. D-
dimer levels were elevated in all volunteers (median maximum value 1748 ng/ml, range 524 –<
5000 ng/ml) and returned within normal range (0–220 ng/ml) during follow-up. The number of
platelets decreased below lower reference value (150x109/L) in 13 volunteers (median lowest
value 127x109/L, range 51–275x109/L) without apparent clinical manifestations of bleeding or
thrombotic complications. Safety parameters returned within normal range in all volunteers
after treatment.
Discussion
Our principle finding is that protection against a heterologous challenge infection with NF135.
C10 is present in NF54 CPS-immunized and protected volunteers challenged more than one
year before. Heterologous protection against NF135.C10 was complete in 15% (2/13) of volun-
teers while there was a delayed patency of more than 48 hours in 54% (7/13) of subjects. Taking
into account a mean multiplication factor of 11.1 [11] and the presumed absence of functional
Fig 2. Protection and prepatent period after heterologous NF135.C10 challenge. Left panels: Kaplan-Meier curves showing percentage of thick smear
negative volunteers after NF135.C10 challenge according to previous NF54 protection status (A) and NF54 CPS-immunization dose (C). Right panels: The
corresponding distribution of prepatent period of thick smear positive volunteers is shown in dot plots according to NF54 protection status (B) and NF54 CPS-
immunization dose (D). Lines represent medians.⊗ = Volunteer presumptively treated after NF54 challenge and considered NF54 protected.
doi:10.1371/journal.pone.0124243.g002
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blood stage immunity at this low parasitemia [3], this delay indicates that liver parasite load
was reduced by approximately 91%. In three out of these seven volunteers a delay of more than
two or three cycles was observed, indicating an estimated reduction of>99%. Three volunteers
with no protection in the earlier homologous NF54 challenge study were also fully susceptible
to NF135.C10.
Previous CPS studies showed that protection is mediated by immunity against pre-erythro-
cytic stages rather than asexual blood stages [3]. NF135.C10 originates from Cambodia, while
NF54, isolated near Schiphol Amsterdam airport, likely originates fromWest Africa [9]. Both
isolates show distinct differences in genes encoding three well-established antigens (MSP-1,
MSP-2 and GLURP) as well as in the rif repetitive elements [9]. The target antigens of CPS-me-
diated protection remain to be elucidated in further studies including possible differences in
antigen-specific responses to NF54 and NF135.C10.
Heterologous protection was incomplete in the majority of NF135.C10 re-challenged volun-
teers demonstrated by a delayed patency compared to controls. Apart from the genetic/anti-
genic variation between NF135.C10 and NF54, and thus insufficient breadth of the induced
immune response, this incomplete heterologous protection may relate to a number of alterna-
tive explanations: i) Waning immunity: the heterologous challenge was performed at 14
months, rather than the usual 2 to 5 months post CPS-immunization; ii) Suboptimal sporozo-
ite immunization dose received by the majority (14/16) of volunteers, indicating an antigen
threshold for complete protection [8]. The minimally required immunization dose may in-
crease for longevity of homologous protection and may be even higher for (long-lasting) heter-
ologous protection. This trial was not powered to detect any dose-response relationships, but
the two fully protected volunteers had indeed been immunized with the medium and high
dose. iii) A possible difference between NF54 and NF135C.10 in sporozoite infectivity for liver
cell invasion and/or maturation. This is supported by the higher first peak of NF135.C10 para-
sitemia was higher compared to historical NF54 controls (2871 Pf/ml versus 456 Pf/ml respec-
tively [11].
Table 1. Protection against NF135.C10 challenge after NF54 CPS-immunization.
NF135.C10 NF135.C10
Protected (n) TS+ (n) Prepatent perioda
NF54 protected
3x15 1 1 12.5
3x10 1 6 10.5 (10.5–15.0)
3x5 0 4 12.0 (9.0–15.5)
all 2 11 10.5 (9.0–15.5)***
NF54 unprotected
3x15 0 0
3x10 0 1 8.5
3x5 0 2 8.8 (7.0–10.5)
all 0 3 8.5 (7.0–10.5)
Malaria-naive controls 0 5 8.5 (8.5–8.5)
Sixteen previously CPS-immunized and challenged with P. falciparum NF54 volunteers in a CPS dose de-escalation and challenge trial were re-
challenged with clone NF135.C10.
aPresented as median (range). N: number of volunteers. TS: Thick smear
***: p = 0.0005 compared to controls
doi:10.1371/journal.pone.0124243.t001
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In partially protected volunteers, delayed patency concurred with earlier onset of AEs. This
might be due to the longer time-frame before parasitemia reaches the thick smear detection
limit. Alternatively, early immune recognition of blood stage parasites by the host may result in
an increased inflammatory response and subsequent increase in AEs. A comparable effect was
observed in a previous trial, where CPS-immunized subjects who received a blood-stage chal-
lenge developed inflammatory markers and fever earlier than naïve controls [3].
Compared to partially protected volunteers, control volunteers showed prolonged AEs after
treatment. This continuation of AEs until day 7 after treatment has not been observed in previ-
ous CHMI trials with either strain NF54 or NF135.C10, neither in the CPS studies nor in RAS
studies [5]. Whether this represents an incidental finding or strain-specific characteristics
needs to be investigated in future trials.
In conclusion, NF54 CPS-immunization induces heterologous protection against the geo-
graphically and genetically distinct P. falciparum NF135.C10 clone. Increasing the immuniza-
tion dose, altering the immunizing strain, or even immunization with a combination of strains
Fig 3. Parasitemia before and after treatment. Parasitemia measured by qPCR up until initiation of treatment (A andC) and from treatment onwards (B
andD) in previously NF54 protected volunteers (A andB) and controls (C and D). Each line represents an individual subject with the same colour before and
after treatment. Values shown as 25 Pf/ml were negative (i.e. half the detection limit of the qPCR: 50 parasites/ml).
doi:10.1371/journal.pone.0124243.g003
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may further improve protection. These results and further optimization of CPS-immunization
regimens will prove highly valuable for the clinical development of whole sporozoite vaccines.
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